Context Therapeutics Inc. (the “Company”), and Tyligand Bioscience, Ltd. (“Tyligand”), today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.
PHILADELPHIA and SHANGHAI, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyligand Bioscience, Ltd. (“Tyligand”), a leader in small molecule drug discovery and development, today announced the successful completion of ONA-XR (onapristone extended release) manufacturing process optimization pursuant to the collaboration agreement entered into between the parties in March 2020.
ONA-XR is an orally administered, potent and specific antagonist of the progesterone receptor (PR) being evaluated in the clinic for PR-positive (PR+) breast, ovarian and endometrial cancers.
In connection with this successful optimization, Context and Tyligand entered into a license agreement whereby Tyligand was granted the exclusive right and sole responsibility for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the “Territory”), and Context is eligible to receive royalties on net sales of ONA-XR in the Territory. Context retains rest of world rights to commercialize ONA-XR.
“We are thrilled to announce this successful optimization work completed for ONA-XR and the execution of the license agreement with Tyligand,” said Martin Lehr, CEO of Context. “This work represents another major step forward for Context’s ability to efficiently scale our manufacturing and clinical capacity to support the development and future commercialization of ONA-XR to address the unmet need in treating women with PR+ cancers.”
“Onapristone has an intriguing molecular structure, and it is no small feat to achieve such a significant improvement in its manufacturing process,” said Peter Wuts, PhD, a pharmaceutical veteran and Senior Advisor to Context. “It is a testament to the drive and creativity of the Tyligand team of molecule builders and the power of chemistry in making better medicines.”
“Tyligand and Context share the commitment of providing effective and affordable treatment options for cancer patients globally and this milestone brings us closer to realizing our goal,” said Tony Zhang, PhD, CEO of Tyligand. “ONA-XR has the potential to be the first-in-class therapeutic agent specifically targeting progesterone receptors and we look forward to working with Context in further developing and commercializing this excellent molecule.”
About Context Therapeutics
Context Therapeutics Inc. is a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. The Company is headquartered in Philadelphia, PA.
About Tyligand, Inc.
Tyligand Bioscience is a Shanghai based clinical stage biotech focusing on the discovery and development of novel small molecule therapeutics to help patients with cancer and autoimmune diseases. The company specializes in creating bispecific ligands for growth signal modulation. For more information on Tyligand, visit www.tyligand.com.
Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
